登录 | 注册    关注公众号  
微信公众号
搜索
 > 【Integrin alpha V beta 6】

Integrin alpha V beta 6信息

英文名称:Integrin alpha-V/beta-6
中文名称:整合素α-V/β-6复合体
靶点别称
上市药物数量:0
临床药物数量:3
最高研发阶段:临床二期

Integrin alpha V beta 6产品列表

 
评论(1)
IT6-H82E4|Biotinylated Human Integrin alpha V beta 6 (ITGAV&ITGB6) Heterodimer Protein, His,Avitag™&Tag Free (MALS verified)
  1. 475XXXXXXX
  2. 0人赞
  3. Great communication from the Acro team--quickly received an email detailing the estimated delivery timeframe and asking if that timeframe was acceptable. Product was ready per the timeline provided by the Acro biosystems team and shipped. This was a new product for us (though we’ve used other acro biosystems products previously) and worked well for our intended use with Surface Plasmon Resonance (SPR). Thank you all!
  4. 2022-04-02
 

Integrin alpha V beta 6 分子别名

Integrin alpha V beta 6,ITGAV&ITGB6

Integrin alpha V beta 6 分子背景

Integrin alpha V beta 6 is a heterodimer of beta-6 associating with alpha-V. Integrin alpha-V beta-6 is a receptor for fibronectin and cytotactin. It recognizes the sequence R-G-D in its ligands. Internalisation of integrin alpha-V beta-6 via clathrin-mediated endocytosis promotes carcinoma cell invasion. Also, Integrin alpha-V beta-6 acts as a receptor for coxsackievirus A9 and coxsackievirus B1 as well as herpes simplex virus-1/HHV-1. Furthermore, it binds the TGF-beta latency‑associated peptide (LAP) and activates TGF-beta 1 or TGF-beta 3 from large latent complexes. This activation requires interaction with LTBP-1 and fibronectin, and is enhanced by PAR-1.

Integrin alpha V beta 6 前沿进展

Integrin alpha V beta 6临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
BG-00011 hu3G9; STX-100; BG-00011 百健 详情
PLN-74809 PLN-74809 Pliant Therapeutics 详情
IDL-2965 IDL-2965 临床二期 Indalo Therapeutics 非酒精性脂肪肝, 特发性肺纤维化 详情
[18F]FP-R01-MG [18F]FP-R01-MG; [18F]FP-R01-MG-F2 临床一期 Pliant Therapeutics, 斯坦福大学, 中国医学科学院北京协和医学院 特发性肺纤维化, 新型冠状病毒肺炎, 胰腺癌, 原发性硬化性胆管炎, 肺癌, 脑转移, 非小细胞肺癌 详情

消息提示

请输入您的联系方式,再点击提交!

确定